drugset
Drugs / Narazaciclib
last change Feb 2026 re-read 9 days ago

Narazaciclib

also known as HX301 · ON123300

Small molecule

Developed for
cancer · endometrial endometrioid adenocarcinoma · glioma · refractory plasma cell neoplasm
Investigated by
Hangzhou Hanx Biopharmaceuticals, Ltd. · Traws Pharma, Inc. · Adriana Rossi

Trials 5

today NCT06703255 · Ph 1/2 NCT06351644 · Ph 1/2 NCT05705505 · Ph 1/2 NCT04739293 · Ph 1 NCT05731934 · Ph 1
2021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT04739293 May 2021 → Oct 2024 — Traws Pharma, Inc. Unknown No outcome recorded
Phase 1 NCT05731934 Sep 2020 → Jan 2024 cancer Hangzhou Hanx Biopharmaceuticals, Ltd. Completed No outcome recorded
Phase 1/23 trials
Phase 1/2 NCT06703255 Jan 2025 → Dec 2026 expected glioma Hangzhou Hanx Biopharmaceuticals, Ltd. Recruiting No outcome recorded
Phase 1/2 NCT06351644 Oct 2024 → Apr 2025 refractory plasma cell neoplasm Adriana Rossi Terminated No outcome recorded
Phase 1/2 NCT05705505 Mar 2023 → Jan 2026 endometrial endometrioid adenocarcinoma Traws Pharma, Inc. Unknown No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as Narazaciclib ClinicalTrials.gov intervention name — accepted as the source's own label NCT05705505 ↗
Known as HX301 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05731934 ↗
1

NCT06703255 ↗
Known as ON123300 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04739293 ↗
1

NCT06351644 ↗
Modality Small molecule — CHEMBL3115681 ↗
Route Oral “Administered Orally as Escalating Daily Doses” NCT04739293 ↗